Cited by 1,167SARS-CoV-2 and COVID-19 ResearchVaccine Coverage and HesitancyCOVID-19 epidemiological studies

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study

Open access

Tartof, Sara Y, Slezak, Jeff M, Fischer, Heidi, Hong, Vennis, Ackerson, Bradley K, Ranasinghe, Omesh N, Frankland, Timothy B, Ogun, Oluwaseye A, Zamparo, Joann M, Gray, Sharon, Valluri, Srinivas R, Pan, Kaije, Angulo, Frederick J, Jodar, Luis, McLaughlin, John M·2021·The Lancet

DOI 10.1016/s0140-6736(21)02183-8PMC PMC8489881

Open this paper in CoChat — free account Open PDF

Abstract

Background Vaccine effectiveness studies have not differentiated the effect of the delta (B.1.617.2) variant and potential waning immunity in observed reductions in effectiveness against SARS-CoV-2 infections. We aimed to evaluate overall and variant-specific effectiveness of BNT162b2 (tozinameran, Pfizer-BioNTech) against SARS-CoV-2 infections and COVID-19-related hospital admissions by time since vaccination among members of a large US health-care system. Methods In this retrospective cohort study, we analysed electronic health records of individuals (≥12 years) who were members of the health-care organisation Kaiser Permanente Southern California (CA, USA), to assess BNT162b2 vaccine effectiveness against SARS-CoV-2 infections and COVID-19-related hospital admissions for up to 6 months. Participants were required to have 1 year or more previous membership of the organisation. Outcomes comprised SARS-CoV-2 PCR-positive tests and COVID-19-related hospital admissions. Effectiveness calculations were based on hazard ratios from adjusted Cox models. This study was registered with ClinicalTrials.gov, NCT04848584. Findings Between Dec 14, 2020, and Aug 8, 2021, of 4 920 549 individuals assessed for eligibility, we included 3 436 957 (median age 45 years [IQR 29-61]; 1 799 395 [52·4%] female and 1 637 394 [47·6%] male). For fully vaccinated individuals, effectiveness against SARS-CoV-2 infections was 73% (95% CI 72-74) and against COVID-19-related hospital admissions was 90% (89-92). Effectiveness against infections declined from 88% (95% CI 86-89) during the first month after full vaccination to 47% (43-51) after 5 months. Among sequenced infections, vaccine effectiveness against infections of the delta variant was high during the first month after full vaccination (93% [95% CI 85-97]) but declined to 53% [39-65] after 4 months. Effectiveness against other (non-delta) variants the first month after full vaccination was also high at 97% (95% CI 95-99), but waned to 67% (45-80) at 4-5 months. Vaccine effectiveness against hospital admissions for infections with the delta variant for all ages was high overall (93% [95% CI 84-96]) up to 6 months. Interpretation Our results provide support for high effectiveness of BNT162b2 against hospital admissions up until around 6 months after being fully vaccinated, even in the face of widespread dissemination of the delta variant. Reduction in vaccine effectiveness against SARS-CoV-2 infections over time is probably primarily due to waning immunity with time rather than the delta variant escaping vaccine protection. Funding Pfizer.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(21)02183-8

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
Khoury, D. S., Cromer, D., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Subbarao, K., Kent, S. J., Triccas, J. A., & Davenport, M. P. (2021) · Nature Medicine · doi:10.1038/s41591-021-01377-8 · Cited by 3,742
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
Lopez Bernal, J., Andrews, N., Gower, C., Gallagher, E., Simmons, R., Thelwall, S., Stowe, J., Tessier, E., Groves, N., Dabrera, G., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108891 · Cited by 2,889
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
Dagan, N., Barda, N., Kepten, E., Miron, O., Perchik, S., Katz, M. A., Hernán, M. A., Lipsitch, M., Reis, B., & Balicer, R. D. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101765 · Cited by 2,527
Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine
Thomas, S. J., Moreira, E. D., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Polack, F. P., Zerbini, C., et al. (2021) · doi:10.1101/2021.07.28.21261159 · Cited by 1,640
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
Thomas, S. J., Moreira, E. D., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Polack, F. P., Zerbini, C., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110345 · Cited by 1,640
Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data
Haas, E. J., Angulo, F. J., McLaughlin, J. M., Anis, E., Singer, S. R., Khan, F., Brooks, N., Smaja, M., Mircus, G., Pan, K., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00947-8 · Cited by 1,564
Self-citation
Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study
Lopez Bernal, J., Andrews, N., Gower, C., Robertson, C., Stowe, J., Tessier, E., Simmons, R., Cottrell, S., Roberts, R., O’Doherty, M., et al. (2021) · BMJ · doi:10.1136/bmj.n1088 · Cited by 1,389
The Development of a Standardized Neighborhood Deprivation Index
Messer, L. C., Laraia, B. A., Kaufman, J. S., Eyster, J. T., Holzman, C., Culhane, J. F., Elo, I. T., Burke, J. G., & O'Campo, P. J. (2006) · Journal of Urban Health · doi:10.1007/s11524-006-9094-x · Cited by 1,046
SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness.
Sheikh, A., McMenamin, J., Taylor, B., & Robertson, C. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01358-1 · Cited by 939

Show all 37 references

Research works printed but not linked: 1

Lopez Bernal, 2021, Effectiveness of Covid-19 vaccines against the B.1.617.2 (delta) variant, N Engl J Med, 385, 585, 10.1056/NEJMoa2108891 · DOI · Paper page

Sorted by citations

Items 601–700 of 1,001

Predicting Vaccine Confidence: Patient Self-advocacy and Fear of COVID-19 in the United States
Croucher, S. M., Murray, N., Ashwell, D., Cullinane, J., & Nguyen, T. T. P. (2022) · Southern Communication Journal · doi:10.1080/1041794x.2022.2099569 · Cited by 7
Antibody responses and SARS-CoV-2 infection after BNT162b2 mRNA booster vaccination among healthcare workers in Japan
Igari, H., Asano, H., Murata, S., Yoshida, T., Kawasaki, K., Kageyama, T., Ikeda, K., Koshikawa, H., Okuda, Y., Urushihara, M., et al. (2022) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2022.07.010 · Cited by 7
A quick scoping review of the first year of vaccination against the COVID-19 pandemic: Do we need more shots or time?
El-Menyar, A. A., Khan, N. A., Mekkodathil, A. A., Rizoli, S. B., Consunji, R. J., Elmenyar, E., Galwankar, S. C., & Al-Thani, H. A. S. (2022) · Medicine · doi:10.1097/md.0000000000030609 · Cited by 7
Economic evaluation of COVID-19 rapid antigen screening programs in the workplace
VILCHES, T. N., Rafferty, E., Wells, C. R., Galvani, A. P., & Moghadas, S. M. (2022) · BMC Medicine · doi:10.1186/s12916-022-02641-5 · Cited by 7
Antibody Responses and Reactogenicity of a Heterologous, Full-Dose Messenger RNA-1273 Booster in Heavily SARS-CoV-2–Exposed CoronaVac-Vaccinated Health-Care Workers in Indonesia: A Real-World Observational Study
Sinto, R., Utomo, D., Suwarti, S., Nelwan, E. J., Surendra, H., Natasha, C., Fransiska, Theresia, D., Ranitria, A. F., Subekti, D., et al. (2022) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.22-0256 · Cited by 12
Acute Adverse Events at a Mass Vaccination Site after the Third and Fourth COVID-19 Vaccinations in Japan
Akaishi, T., Onodera, T., Takahashi, T., Harigae, H., & Ishii, T. (2023) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.2023.j002 · Cited by 7
COVID-19 Vaccines—All You Want to Know
Shishido, A. A., Barnes, A. H., Narayanan, S., & Chua, J. V. (2023) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0042-1759779 · Cited by 6
Peri-infection titers of neutralizing and binding antibodies as a predictor of COVID-19 breakthrough infections in vaccinated healthcare professionals: importance of the timing
Gillot, C., Bayart, J., Closset, M., Cabo, J., Maloteau, V., Dogné, J., Douxfils, J., & Favresse, J. (2023) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2023-0134 · Cited by 9
An update on studies characterizing adaptive immune responses in SARS-CoV-2 infection and COVID-19 vaccination
Antunes, R. D. S., Grifoni, A., Frazier, A., Weiskopf, D., & Sette, A. (2023) · International Immunology · doi:10.1093/intimm/dxad014 · Cited by 8
Effectiveness of Inactivated and mRNA COVID-19 Vaccines Against SARS-CoV-2 Infection, Severe Disease and Mortality in the Geriatric Population
Bahçe, Y. G., Acer, Ö., & Özüdoğru, O. (2023) · Current Microbiology · doi:10.1007/s00284-023-03322-z · Cited by 7
Changes in COVID-19 vaccine hesitancy at different times among residents in Guangzhou, China
Chen, L., Li, Z., Lu, X., Deng, Y., Lu, K., Li, T., Lü, L., Wang, Z., & Lü, J. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1164475 · Cited by 7
NAC1 confines virus‐specific memory formation of CD4+ T cells through the ROCK1‐mediated pathway
Wang, L., Peng, H., Das, J. K., Kumar, A., Ren, Y., Ballard, D. J., Xiong, X., Yang, W., Ren, X., de Figueiredo, P., et al. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28957 · Cited by 7
SARS-CoV-2 vaccine breakthrough infection in the older adults: a meta-analysis and systematic review
Jing, X., Han, M., Wang, X., & Zhou, L. (2023) · BMC Infectious Diseases · doi:10.1186/s12879-023-08553-w · Cited by 9
Protection of COVID-19 Vaccination Against Hospitalization During the Era of Omicron BA.4 and BA.5 Predominance: A Nationwide Case–Control Study Based on the French National Health Data System
Semenzato, L., Botton, J., Vu, S. L., Jabagi, M.-J., Cuenot, F., Drouin, J., Dray‐Spira, R., Weill, A., & Zureik, M. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad460 · Cited by 8
An agent-based model with antibody dynamics information in COVID-19 epidemic simulation
Xu, Z., Song, J., Liu, W., & Wei, D. (2023) · Infectious Disease Modelling · doi:10.1016/j.idm.2023.11.001 · Cited by 7
Determinants of SARS-CoV-2 IgG response and decay in Canadian healthcare workers: A prospective cohort study
Cherry, N., Adisesh, A., Burstyn, I., Charlton, C. L., Chen, Y., Durand-Moreau, Q. V., Labrèche, F., Ruzycki, S. M., Turnbull, L., Zadunayski, T., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.01.052 · Cited by 8
The effectiveness of BNT162b2 mRNA vaccine against COVID-19 caused by Delta variant of SARS-CoV-2: a systematic review and meta-analysis
Kow, C. S., Ramachandram, D. S., & Hasan, S. S. (2022) · Inflammopharmacology · doi:10.1007/s10787-021-00915-7 · Cited by 7
Rapid Evaluation of Vaccine Booster Effectiveness against SARS-CoV-2 Variants
Cheng, H. L., Lim, S. M., Jia, H., Chen, M. W., Ng, S. Y., Gao, X., Somani, J., Sengupta, S., Tay, D. M. Y., Chua, P. W. L., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.02257-22 · Cited by 7
The COVID-19 Vaccination Coverage in ICU Patients with Severe COVID-19 Infection in a Country with Low Vaccination Coverage—A National Retrospective Analysis
Văleanu, L., Andrei, S., Moroşanu, B., Longrois, D., Bubenek-Turconi, Ş.-I., & Collaborative, C.-R. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12051749 · Cited by 7
Serum anti-Spike antibody titers before and after heterologous booster with mRNA-1273 SARS-CoV-2 vaccine following two doses of inactivated whole-virus CoronaVac vaccinePreprint
Sinto, R., Utomo, D., Suwarti, S., Nelwan, E. J., Surendra, H., Natasha, C., Fransiska, Theresia, D., Ranitria, A. F., Subekti, D., et al. (2021) · medRxiv · doi:10.1101/2021.12.24.21268360 · Cited by 7
Effectiveness of COVID-19 vaccines
Syed, M. A., Qotba, H. A. A., & Alnuaimi, A. S. (2022) · Journal of Infection · doi:10.1016/j.jinf.2022.02.034 · Cited by 7
The efficacy, safety and immunogenicity Nanocovax: results of a randomized, double-blind, placebo-controlled Phase 3 trialPreprint
Nguyen, T. P., Đỗ, Q., Lan, P. T., Anh, Đ. Đ., Khong, H., Nguyễn, T. V., Hoang, L. V., Dinh, D. V., Pham, H. N., Chu, M. V., et al. (2022) · medRxiv · doi:10.1101/2022.03.22.22272739 · Cited by 7
Increasing SARS-CoV2 cases, hospitalizations, and deaths among the vaccinated populations during the Omicron (B.1.1.529) variant surge in UKPreprint
Emani, V. R., Pallipuram, V. K., Goswami, K. K., Maddula, K. R., Reddy, R., Nakka, A. S., Panga, S., Reddy, N. K., Reddy, N. K., Nandanoor, D., et al. (2022) · medRxiv · doi:10.1101/2022.06.28.22276926 · Cited by 7
Analyzing the worldwide progression of COVID-19 cases and deaths using nonlinear mixed-effects model
Koshimichi, H., & Hisaka, A. (2024) · PLoS ONE · doi:10.1371/journal.pone.0306891 · Cited by 6
Enhanced durability of a Zika virus self-amplifying RNA vaccine through combinatorial OX40 and 4-1BB agonism
Lu, H.-H., Alves, R. P. D. S., Li, Q. H., Eder, L., Timis, J., Madany, H., Chuensirikulchai, K., Varghese, K., Singh, A. D., Tran, L. L., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.187405 · Cited by 7
mRNA technology for the prevention and treatment of HIV-1 infection
Chuang, L. I. U., Yaremenko, A. V., Li, X., You, X., Zhu, X., Liu, N., Chen, W., Kong, N., Xie, T., Gaiha, G. D., et al. (2026) · Nature Reviews Bioengineering · doi:10.1038/s44222-025-00387-2 · Cited by 6
SNHG5 knockdown alleviates neuropathic pain induced by chronic constriction injury via sponging miR‑142‑5p and regulating the expression of CAMK2A
Jin, S. C., Tian, S., Ding, H., Yu, Z., & Li, M. (2022) · Molecular Medicine Reports · doi:10.3892/mmr.2022.12737 · Cited by 6
Real-World COVID-19 Vaccine Protection Rates against Infection in the Delta and Omicron Eras
Zhu, Y., Gu, J., Qiu, Y., & Chen, S. X. (2023) · Research · doi:10.34133/research.0099 · Cited by 6
Real-world effectiveness of mRNA COVID-19 vaccines in the elderly during the Delta and Omicron variants: Systematic review
Palalay, H., Vyas, R., & Tafuto, B. A. (2023) · World Journal of Meta-Analysis · doi:10.13105/wjma.v11.i5.167 · Cited by 7
A novel multivariate time series forecasting dendritic neuron model for COVID-19 pandemic transmission tendency
Tang, C. C., Todo, Y., Kodera, S., Sun, R., Shimada, A., & Hirata, A. (2024) · Neural Networks · doi:10.1016/j.neunet.2024.106527 · Cited by 6
Immunogenicity and safety of different combinations involving a third booster dose of SARS-CoV-2 inactivated vaccine, inactivated quadrivalent influenza vaccine, and 23-valent pneumococcal polysaccharide vaccine in adults aged ≥60 years: a phase 4, randomized, open-label study
Bai, S., Zhou, S., Zhang, J., Chen, W., Lv, M., Wang, J., Zhang, A., Wu, J., & Zhao, W. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1437267 · Cited by 6
Relative Effectiveness and Waning of a Third Dose of mRNA COVID-19 Vaccine in Medicare Beneficiaries Aged 65 Years and Older During the BA.1/BA.2 Omicron Period
Lu, Y., Matuska, K., McEvoy, R., Izurieta, H. S., Hervol, J. R., Menis, M. D., Lindaas, A., Steele, W. R., Chillarige, Y., Wernecke, M., et al. (2024) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiae503 · Cited by 7
Significance of Initial Chest CT Severity Score (CTSS) and Patient Characteristics in Predicting Outcomes in Hospitalized COVID-19 Patients: A Single Center Study
Milenkovic, A., Nikolić, S., Elek, Z., Pribaković, J. A., Ilić, A., Bulatović, K., Gašić, M., Jaksic, B. S., Stojanovic, M., Jaksic, D. M., et al. (2024) · Viruses · doi:10.3390/v16111683 · Cited by 6
Co-immunization with spike and nucleocapsid based DNA vaccines for long-term protective immunity against SARS-CoV-2 Omicron
Pinto, P. B. A., Timis, J., Chuensirikulchai, K., Li, Q. H., Lu, H.-H., Maule, E., Nguyen, M. N., Alves, R. P. D. S., Verma, S. K., Ana‐Sosa‐Batiz, F., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-01043-3 · Cited by 8
Viral replication dynamics could critically modulate vaccine effectiveness and should be accounted for when assessing new SARS‐CoV‐2 variants
Yang, W., & Shaman, J. L. (2022) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.12961 · Cited by 5
Effect of COVID-19 Vaccination Campaign in Belgian Nursing Homes on COVID-19 Cases, Hospital Admissions, and Deaths among Residents
Dequeker, S., Callies, M., Vernemmen, C., Latour, K., Panis, L. I., Mahieu, R., Noppe, L., Savsin, M., & Duysburgh, E. (2022) · Viruses · doi:10.3390/v14071359 · Cited by 7
Rehabilitación física en pacientes con obesidad post COVID19: Una revisión narrativa
Pino-Zúñiga, J., Cancino, J., González, L., Troncoso, E., Horta, P., & Cancino, J. (2022) · Revista chilena de nutrición · doi:10.4067/s0717-75182022000100108 · Cited by 6
Spike Mutation Profiles Associated With SARS-CoV-2 Breakthrough Infections in Delta Emerging and Predominant Time Periods in British Columbia, Canada
Fibke, C. D., Joffres, Y., Tyson, J. R., Colijn, C., Janjua, N. Z., Fjell, C. D., Prystajecky, N., Jassem, A. N., & Sbihi, H. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.915363 · Cited by 7
Dynamicity and persistence of severe acute respiratory syndrome coronavirus-2 antibody response after double dose and the third dose with BBV-152 and AZD1222 vaccines: A prospective, longitudinal cohort study
Parai, D., Choudhary, H. R., Dash, G. C., Behera, S., Mishra, N., Pattnaik, D., Raghav, S. K., Mishra, S. K., Sahoo, S. K., Swain, A., et al. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.942659 · Cited by 5
Lessons from a large-scale COVID-19 vaccine trial
Mahla, R. S., & Dustin, L. B. (2022) · Journal of Clinical Investigation · doi:10.1172/jci163202 · Cited by 6
The Longitudinal Analysis on the Anti-SARS-CoV-2 Antibodies among Healthcare Workers in Poland—Before and after BNT126b2 mRNA COVID-19 Vaccination
Lorent, D., Nowak, R., Luwański, D., Pisarska-Krawczyk, M., Figlerowicz, M., & Zmora, P. (2022) · Vaccines · doi:10.3390/vaccines10101576 · Cited by 8
Evidence of premature lymphocyte aging in people with low anti-spike antibody levels after BNT162b2 vaccination
Huang, Y., Shin, J. E., Xu, A. M., Yao, C., Joung, S. Y., Wu, M., Zhang, R., Shin, B., Foley, J., Mahov, S., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105209 · Cited by 5
Waning of Humoral Immunity and the Influencing Factors after BNT162b2 Vaccination: A Cohort Study with a Latent Growth Curve Model in Fukushima
Kobashi, Y., Takebayashi, Y., Yoshida, M., Kawamura, T., Shimazu, Y., Kaneko, Y., Nishikawa, Y., Nakayama, A., Takita, M., Zhao, T., et al. (2022) · Vaccines · doi:10.3390/vaccines10122007 · Cited by 5
In Silico Screening of Prospective MHC Class I and II Restricted T-Cell Based Epitopes of the Spike Protein of SARS-CoV-2 for Designing of a Peptide Vaccine for COVID-19
Sarma, K., Bali, N. K., Sarmah, N., & Borkakoty, B. (2022) · COVID · doi:10.3390/covid2120124 · Cited by 6
Hybrid immunity and protection against infection during the Omicron wave in Malta
Cauchi, J. P., Džiugytė, A., Borg, M., Melillo, T., Zahra, G., Barbara, C., Souness, J., Agius, S., Calleja, N., Gauci, C., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2156814 · Cited by 6
T Cell Responses Correlate with Self-Reported Disease Severity and Neutralizing Antibody Responses Predict Protection against SARS-CoV-2 Breakthrough Infection
Zhao, Z., Kumánovics, A., Love, T., Melanson, S. E. F., Meng, Q. H., Wu, A. H. B., Wiencek, J. R., Apple, F. S., Ondracek, C. R., Koch, D. D., et al. (2023) · Viruses · doi:10.3390/v15030709 · Cited by 6
Chest CT features of COVID-19 in vaccinated versus unvaccinated patients: use of CT severity score and outcome analysis
Masci, G. M., Izzo, A., Bonito, G., Marchitelli, L., Guiducci, E., Ciaglia, S., Lucchese, S., Corso, L., Valenti, A., Malzone, L., et al. (2023) · La radiologia medica · doi:10.1007/s11547-023-01664-z · Cited by 7
A Qualitative Study on Barriers to COVID-19 Vaccine Uptake among Community Members in Tanzania
Mgongo, M., Manongi, R. N., Mboya, I. B., Ngocho, J. S., Amour, C., Mtei, M., Bilakwate, J. S., Nyaki, A. Y., George, J. M., Leyaro, B. J., et al. (2023) · Vaccines · doi:10.3390/vaccines11081366 · Cited by 6
Incidence and Severity of SARS-CoV-2 Infections in People With Primary Ciliary Dyskinesia
Pedersen, E. S. L., Schreck, L. D., Goutaki, M., Bellu, S., Copeland, F., Lucas, J. S., Zwahlen, M., & Kuehni, C. E. (2023) · International Journal of Public Health · doi:10.3389/ijph.2023.1605561 · Cited by 6
Differences in leucocytes and inflammation-based indices among critically ill patients owing to SARS-CoV-2 variants during several successive waves of COVID-19 pandemic
Jemaa, A. B., Oueslati, R., Guissouma, J., Ghadhoune, H., Ali, H. B., Allouche, H., Trabelsi, I., Samet, M., & Brahmi, H. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110836 · Cited by 6
Encouraging COVID-19 vaccination by focusing on anticipated affect: A scoping review
Okuhara, T., Shirabe, R., Kagawa, Y., Okada, H., & Kiuchi, T. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e22655 · Cited by 6
Estimates of Presumed Population Immunity to SARS-CoV-2 by State in the United States, August 2021
Stoner, M. C. D., Angulo, F. J., Rhea, S. K., Brown, L. M., Atwell, J. E., Nguyen, J. L., McLaughlin, J. M., Swerdlow, D. L., & MacDonald, P. D. M. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab647 · Cited by 6
Self-citation
Assessment of the Effectiveness of Omicron Transmission Mitigation Strategies for European Universities Using an Agent-Based Network Model
Lasser, J., Hell, T., & García, D. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac340 · Cited by 6
Evaluation of BNT162b2 vaccine effectiveness in Malaysia: test negative case-control study
Lim, A. H., Rahman, N. A., Ong, S. M., Paraja, J., Rashid, R., Parmar, I. S., Dahlan, S. N., Tan, Z. S. S., Bohari, I., Peariasamy, K. M., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.08.032 · Cited by 6
Post-Trans Human Techno Science as Help or Threat: An Overview with Emphasis on a Current Nanotechnology Application
Sia, P. D. (2022) · Ergonomics International Journal · doi:10.23880/eoij-16000293 · Cited by 6
Levels of SARS-CoV-2 Antibodies Among Fully-Vaccinated Individuals With Delta or Omicron Variant Breakthrough Infections: A Prospective Cohort StudyPreprint
Stærke, N. B., Reekie, J., Nielsen, H., Benfield, T., Wiese, L., Knudsen, L. S., Iversen, M. B., Iversen, K. K., Fogh, K., Bodilsen, J., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4066425 · Cited by 6
The time between vaccination and infection impacts immunity against SARS-CoV-2 variantsPreprint
Bates, T. A., Leier, H. C., McBride, S. K., Schoen, D., Lyski, Z. L., Lee, D. X., Messer, W. B., Curlin, M. E., & Tafesse, F. (2023) · medRxiv · doi:10.1101/2023.01.02.23284120 · Cited by 6
Humoral and Cellular Response and Associated Variables Nine Months following BNT162b2 Vaccination in Healthcare Workers
Syrimi, N., Sourri, F., Giannakopoulou, M.-C., Karamanis, D., Pantousas, A., Georgota, P., Rokka, E., Vladeni, Z., Tsiantoula, E., Soukara, E., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12093172 · Cited by 5
Pandemic Open Data: Blessing or Curse?
Rinner, C. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.1001594 · Cited by 5
Effectiveness of the BNT162b2 and the CoronaVac vaccines and boosters in healthcare workers
Çulpan, H. C., Aydın, S. N., Uygur, A., Sayılı, U., Şeker, E., Balkan, İ. İ., Karaali, R., Budak, B., Keskindemirci, Y., Saltoğlu, N., et al. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2275445 · Cited by 5
Cross-sectional and longitudinal genotype to phenotype surveillance of SARS-CoV-2 variants over the first four years of the COVID-19 pandemic
Akerman, A., Fichter, C., Milogiannakis, V., Esneau, C., Silva, M. R., Ison, T., Lopez, J. A., Naing, Z., Caguicla, J., Amatayakul‐Chantler, S., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105415 · Cited by 7
SARS-CoV-2 vaccine boosters: The time to act is now
Petersen, M. L., Schwab, J., & Havlir, D. V. (2021) · PLoS Medicine · doi:10.1371/journal.pmed.1003882 · Cited by 4
High heterogeneity on the accepted vaccines for COVID-19 certificates in European countries
Dal‐Ré, R., Banzi, R., Becker, S. L., Launay, O., & Pavli, A. (2022) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2022.102321 · Cited by 5
Long‐term effects of homologous and heterologous SARS‐CoV ‐2 vaccination on humoral and cellular immune responses
Hollstein, M. M., Münsterkötter, L., Schön, M. P., Bergmann, A., Husar, T. M., Abratis, A., Eidizadeh, A., Dierks, S., Schaffrinski, M., Zachmann, K., et al. (2022) · Allergy · doi:10.1111/all.15373 · Cited by 5
A country-specific model of COVID-19 vaccination coverage needed for herd immunity in adult only or population wide vaccination programme
Goh, F. T., Chew, Y. Z., Tam, C. C., Yung, C. F., & Clapham, H. (2022) · Epidemics · doi:10.1016/j.epidem.2022.100581 · Cited by 5
The potential of developing a protective peptide‐based vaccines against SARS‐CoV‐2
Shalash, A. O., Tóth, I., & Skwarczyński, M. (2022) · Drug Development Research · doi:10.1002/ddr.21969 · Cited by 6
Vaccine Coverage Associated With Ending a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Wave: A Retrospective Longitudinal Analysis
Glatman‐Freedman, A., Feldman, S. F., Hershkovitz, Y., Kaufman, Z., Dichtiar, R., Keinan‐Boker, L., & Bromberg, M. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac524 · Cited by 6
SARS-CoV-2 infection risk among vaccinated and unvaccinated household members during the Alpha variant surge – Denver, Colorado, and San Diego, California, January–April 2021
McCormick, D. W., Konkle, S. L., Magleby, R., Chakrabarti, A. K., Cherney, B., Lindell, K., Namageyo-Funa, A., Visser, S. N., Soto, R. A., Donnelly, M. A. P., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.06.066 · Cited by 5
The effect of the third dose of the BNT162b2 vaccine on anti-SARS-CoV-2 spike antibody levels in healthcare workers with and without COVID-19 infection
Wolszczak-Biedrzycka, B., Bieńkowska, A., Cieślikiewicz, B., Smolińska-Fijołek, E., Biedrzycki, G., & Dorf, J. (2023) · Annals of Medicine · doi:10.1080/07853890.2023.2182907 · Cited by 7
Dynamics of SARS-CoV-2 Spike-IgG throughout Three COVID-19 Vaccination Regimens: A 21-Month Longitudinal Study of 82 Norwegian Healthcare Workers
Augustinussen, M. H., Tylden, G. D., & Rinaldo, C. H. (2023) · Viruses · doi:10.3390/v15030619 · Cited by 7
Estimated US Pediatric Hospitalizations and School Absenteeism Associated With Accelerated COVID-19 Bivalent Booster Vaccination
Fitzpatrick, M. C., Moghadas, S. M., VILCHES, T. N., Shah, A., Pandey, A., & Galvani, A. P. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.13586 · Cited by 5
Real time monitoring of COVID-19 intervention effectiveness through contact tracing data
Gibson, G., Woody, S., James, E. R., Weldon, M., Fox, S. J., Ancel, L. W., & Bhavnani, D. (2023) · Scientific Reports · doi:10.1038/s41598-023-35892-0 · Cited by 5
Cost-effectiveness analysis of COVID-19 variants effects in an age-structured model
Cho, G., Kim, Y. J., Seo, S.-H., Jang, G., & Lee, H. (2023) · Scientific Reports · doi:10.1038/s41598-023-41876-x · Cited by 5
Analysis of the COVID-19 vaccine willingness and hesitancy among parents of healthy children aged 6 months–4 years: a cross-sectional survey in Italy
Postiglione, M., del Giudice, G. M., Polla, G. D., & Angelillo, I. F. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1241514 · Cited by 5
BNT162b2 Booster Dose Elicits a Robust Antibody Response in Subjects with Abdominal Obesity and Previous SARS-CoV-2 Infection
Malavazos, A. E., Dubini, C., Milani, V., Boveri, S., Meregalli, C., Bertolini, C., Buscemi, C., Cardani, R., Renna, L. V., Trevisan, M. B., et al. (2023) · Vaccines · doi:10.3390/vaccines11121796 · Cited by 6
Long-Term Analyses of SARS-CoV-2 Humoral and T Cell Responses and Breakthrough SARS-CoV-2 Infections after Two Doses of BNT162b2 Followed by mRNA-1273 and Bivalent Omicron-Adapted BNT162b2 Vaccines: A Prospective Study over 2 Years in Non-Immunocompromised Individuals
Erice, A., Prieto, L., & Caballero, C. (2023) · Vaccines · doi:10.3390/vaccines11121835 · Cited by 5
Cell immunity to SARS-CoV-2 after natural infection and/or different vaccination regimens
Culebras, E., Martínez, M., Novella, C., León, J. M., Marcos, E., Delgado‐Iribarren, A., & Ríos, E. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1370859 · Cited by 6
Elucidating vaccine efficacy using a correlate of protection, demographics, and logistic regression
Dudášová, J., Valenta, Z., & Sachs, J. R. (2024) · BMC Medical Research Methodology · doi:10.1186/s12874-024-02197-3 · Cited by 5
Evaluation of SARS-CoV-2 anti-Spike antibody levels and breakthrough infection risk among vaccinated adults in North Lebanon
Nour, D., Ismail, M. B., Osman, M., Rafei, R., Kasir, D., Dabboussi, F., Colson, P., & Hamzé, M. (2024) · PLoS ONE · doi:10.1371/journal.pone.0302579 · Cited by 5
Duration of effectiveness of the COVID-19 vaccine in Japan: a retrospective cohort study using large-scale population-based registry data
Uemura, K., Ono, S., Michihata, N., Yamana, H., & Yasunaga, H. (2024) · BMC Infectious Diseases · doi:10.1186/s12879-024-09488-6 · Cited by 4
Tracking vaccine effectiveness in an evolving pandemic, countering misleading hot takes and epidemiologic fallacies
Morris, J. S. (2024) · American Journal of Epidemiology · doi:10.1093/aje/kwae280 · Cited by 5
Genome diversity of SARS-CoV-2 lineages associated with vaccination breakthrough infections in Addis Ababa, Ethiopia
Aga, A. M., Mulugeta, D., Gebreegziabxier, A., Zeleke, G. T., Girmay, A. M., Tura, G. B., Ayele, A., Mohammed, A. A., Belete, T., Taddele, T., et al. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-11107-x · Cited by 5
Messenger ribonucleic acid vaccines for severe acute respiratory syndrome coronavirus-2 – a review
Akamine, C. M., & Sahly, H. M. E. (2021) · Translational research · doi:10.1016/j.trsl.2021.12.007 · Cited by 5
Neutralizing Antibodies Responses against SARS-CoV-2 in a Sardinian Cohort Group Up to 9 Months after BNT162b2 Vaccination
Sanna, G., Marongiu, A., Firinu, D., Piras, C., Franci, G., Galdiero, M., Pala, G., Palmas, V., Angius, F., Littera, R., et al. (2022) · Vaccines · doi:10.3390/vaccines10040531 · Cited by 5
Assessing real-world vaccine effectiveness against severe forms of SARS-CoV-2 infection: an observational study from routine surveillance data in Switzerland
Anderegg, N., Althaus, C. L., Colin, S., Hauser, A., Laube, A., Mäusezahl, M., Wagner, M., Zaffora, B., & Riou, J. (2022) · Swiss Medical Weekly · doi:10.4414/smw.2022.w30163 · Cited by 5
Opinion Polls and Antibody Response Dynamics of Vaccination with COVID-19 Booster Vaccines
Wu, Y., Li, H., Wang, Y., Huang, P., Xu, Y., Xu, Y., Zhao, Q., Zhou, Y., Wang, J., Ji, M., et al. (2022) · Vaccines · doi:10.3390/vaccines10050647 · Cited by 5
Booster Vaccination Strategies for “Living With COVID-19”
Kim, J. E., ‍Lee, S., & Kim, H. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.896713 · Cited by 7
Testing Frequency Matters: An Evaluation of the Diagnostic Performance of a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Rapid Antigen Test in US Correctional Facilities
Lind, M. L., Schultes, O. L., Robertson, A. J., Houde, A. J., Cummings, D. A. T., Ko, A. I., Kennedy, B. S., & Richeson, R. P. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac450 · Cited by 5
Follow up of the Humoral Response in Healthcare Workers after the Administration of Two Dose of the Anti SARS-CoV-2 Vaccines—Effectiveness in Delta Variant Breakthrough Infections
Fernández‐Rivas, G., Barallat, J., Quirant‐Sánchez, B., González, V., Doladé, M., Martínez-Cáceres, E. M., Piña, M., Matlló, J., Blanco, I., & Cardona, P.-J. (2022) · Viruses · doi:10.3390/v14071385 · Cited by 5
Coronavirus Disease 2019 Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection in the United States Before the Delta- and Omicron-Associated Surges: A Retrospective Cohort Study of Repeat Blood Donors
Grebe, E., Yu, E. A., Bravo, M. D., Welte, A., Bruhn, R. L., Stone, M., Green, V., Williamson, P. C., Feldstein, L. R., Jones, J. M., et al. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac318 · Cited by 5
Estimation of mRNA COVID-19 Vaccination Effectiveness in Tokyo for Omicron Variants BA.2 and BA.5: Effect of Social Behavior
Kodera, S., Niimi, Y., Rashed, E. A., Yoshinaga, N., Toyoda, M., & Hirata, A. (2022) · Vaccines · doi:10.3390/vaccines10111820 · Cited by 5
Accuracy of COVID-19–Like Illness Diagnoses in Electronic Health Record Data: Retrospective Cohort Study
Rao, S., Bozio, C. H., Butterfield, K. A., Reynolds, S. B., Reese, S. E., Ball, S. W., Steffens, A., Demarco, M., McEvoy, C., Thompson, M. G., et al. (2022) · JMIR Formative Research · doi:10.2196/39231 · Cited by 5
BNT162b2 Against COVID-19-Associated Emergency Department and Urgent Care Visits Among Children 5–11 Years of Age: A Test Negative Design
Tartof, S. Y., Frankland, T. B., Puzniak, L., Slezak, J. M., Hong, V. X., Takhar, H. S., Ogun, O. A., Simmons, S. R., Xie, F., Zamparo, J. M., et al. (2023) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piad005 · Cited by 5
Self-citation
Immunogenicity and reactogenicity of heterologous immunization schedules with COVID-19 vaccines: a systematic review and network meta-analysis
Li, P., Wang, W., Tao, Y., Tan, X., Li, Y., Mao, Y., Gao, L., Feng, L., Zhan, S., & Sun, F. (2023) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002567 · Cited by 5
Public Choice Theory: An Explanation of the Pandemic Policy Responses
Karadimas, P. (2023) · Studies in Public Choice · doi:10.1007/978-3-031-24967-9_5 · Cited by 6
Quantifying the benefits of customized vaccination strategies: A network‐based optimization approach
Li, S., & Aprahamian, H. (2023) · Naval Research Logistics (NRL) · doi:10.1002/nav.22134 · Cited by 5
Hospitalization Among Patients Treated With Molnupiravir: A Retrospective Study of Administrative Data
Prajapati, G., Das, A. K., Sun, Y., & Fonseca, E. (2023) · Clinical Therapeutics · doi:10.1016/j.clinthera.2023.07.018 · Cited by 5
Twenty-Month Monitoring of Humoral Immune Response to BNT162b2 Vaccine: Antibody Kinetics, Breakthrough Infections, and Adverse Effects
Walory, J., Książek, I., Karyński, M., & Baraniak, A. (2023) · Vaccines · doi:10.3390/vaccines11101578 · Cited by 5
Breakthrough infections after COVID-19 vaccinations do not elicit platelet hyperactivation and are associated with high platelet–lymphocyte and low platelet–neutrophil aggregates
Maiorca, F., Lombardi, L., Marrapodi, R., Pallucci, D., Sabetta, A., Zingaropoli, M. A., Perri, V., Flego, D., Romiti, G. F., Corica, B., et al. (2023) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2023.102262 · Cited by 5
Boosters appear effective, but are they always needed?
Reddy, K. S. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02388-6 · Cited by 5

Authors: Tartof, S. Y., Slezak, J. M., Fischer, H., Hong, V., Ackerson, B. K., Ranasinghe, O. N., Frankland, T. B., Ogun, O. A., Zamparo, J. M., Gray, S., Valluri, S. R., Pan, K., Angulo, F. J., Jodar, L., & McLaughlin, J. M.
Affiliations: Kaiser Permanente (US)
Pfizer (United States) (US)
Corresponding author: Tartof, Sara Y
ORCID: Tartof, Sara Y
Slezak, Jeff M
Fischer, Heidi
Hong, Vennis
Ackerson, Bradley K
Ranasinghe, Omesh N
Frankland, Timothy B
Valluri, Srinivas R
Angulo, Frederick J
Venue: The Lancet
Publisher: Elsevier BV
Published: 2021-10
Volume: 398
Issue: 10309
Pages: 1407-1416
ISSN: 0099-5355 (ISSN-L)
0140-6736
DOI: 10.1016/s0140-6736(21)02183-8
PMC: PMC8489881
OpenAlex: W3202826390
Cited by: 1,167
References: 37
Citations by year: 2026: 33 · 2025: 70 · 2024: 116 · 2023: 257 · 2022: 583 · 2021: 108
FWCI: 84.33
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
doi.org/10.15223/policy-017 (stm-asf)
doi.org/10.15223/policy-037 (stm-asf)
doi.org/10.15223/policy-012 (stm-asf)
doi.org/10.15223/policy-029 (stm-asf)
doi.org/10.15223/policy-004 (stm-asf)
Locations: The Lancet (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: Pfizer Inc Boulder
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Social Sciences › Health › Vaccine Coverage and Hesitancy
Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
Keywords: BNT162b2, COVID-19 vaccines, mRNA vaccines, vaccine effectiveness, COVID-19 pandemic, COVID-19 hospitalization, Delta variant, waning immunity, integrated health system, Kaiser Permanente, time since vaccination, SARS-CoV-2 sequencing
MeSH terms: COVID-19, SARS-CoV-2, COVID-19 Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Aged, 80 and over, Child, Female, Hospitalization, Humans, Male, Middle Aged, Organizations, Retrospective Studies, RNA, Messenger, Time Factors, United States, Vaccination, Delivery of Health Care, Integrated

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks